La cadena de opciones muestra datos clave de las opciones de acciones de Smart Sand a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Smart Sand..

Smart Sand (NASDAQ:SND) Bolsa, Cadena de Opciones

Smart Sand

Smart Sand Inc is a fully integrated frac sand supply and services company that offers complete mine-to-well site proppant supply and logistics solutions. It produces Northern White frac sand, which is a premium proppant used to enhance hydrocarbon recovery rates in the hydraulic fracturing of oil and natural gas wells. Its product portfolio includes Smart System, which includes SmartBelt, SmartDepot Silo and SmartPath Loader. The company caters its products and services to oil and natural gas exploration and production companies and oilfield service companies. The majority of its revenue comes from Sand Sales, followed by logistics.

Smart Sand Inc

Sonida Senior Living Inc

RedHawk Holdings Corp

SANDFIRE RES NL UNSP/ADR by Sandfire Resources NL

Sandfire Resources Ltd

SNDL Inc

Schneider National Inc

SCANDINAVIAN TOB GRP ORD by Scandinavian Tob Group AS

Scandinavian Tobacco Group AS

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals Inc

SUNRIDGE INTL INC by Sunridge International, Inc.

Sunridge International Inc

News

BSFC

Blue Star Foods Inks Vendor Agreement With Lowtide, Under Wicked Tuna Seafood & Toby Keith's Premium Brands

Wells Fargo analyst Whit Mayo maintains Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) with a Overweight and raises the price target from $52 to $56.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Bank of America, Raises Price Target to $56

Truist Securities analyst Ki Bin Kim maintains Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) with a Buy and raises the price target from $28 to $31.

Truist Securities Maintains Buy on Brixmor Property Group, Raises Price Target to $31

Wedbush analyst Nick Setyan reiterates Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Outperform and maintains $47 price target.

Reiteration

Wedbush Reiterates Outperform on Dine Brands Global, Maintains $47 Price Target

Piper Sandler analyst Edward Tenthoff maintains Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) with a Overweight and lowers the price target from $9 to $4.

OMGA

Piper Sandler Maintains Overweight on Omega Therapeutics, Lowers Price Target to $4

WIIM

BABA

Alibaba Group Holding shares are trading higher after the company reported better-than-expected Q2 sales results.

Piper Sandler analyst Kashy Harrison upgrades Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) from Neutral to Overweight and raises the price target from $10 to $20.

Upgrades

Piper Sandler Upgrades Bloom Energy to Overweight, Raises Price Target to $20

AMAT

Applied Materials shares are trading lower following Q1 financial results. Also, multiple firms lowered their respective price targets on the stock.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) with a Buy and maintains $4 price target.

PGEN

HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $4 Price Target

The World Health Organization (WHO) on Friday described vaccines as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived childhood without them. This comes at after Donald Trump&#8216;s announcement of Robert F. Kennedy Jr. as Health Secretary.
What Happened: As per <a href="https://pro.benzinga.com">Benzinga Pro</a> on Friday, health stocks declined further during pre-market hours. Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) saw a 0.58% drop after closing 2.62% lower at $26.02. Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) was down by 1.56% while AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell by 1.41%, and Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) decreased by 1.39%, having already dropped 7.02% to $7.22.
While the spokesperson for WHO did not comment on Kennedy Jr&#8217;s appointment directly, she mentioned that the U.S. is an important United Nations member and hoped the &#8220;fantastic work&#8221;&nbsp; would continue, <a href="https://www.bbc.com/news/live/c0lp93494g9t?post=asset%3Afdf8e84f-8eb1-45b0-9e05-4ad5adad709b#post">as</a> per BBC news.
Trump&#8217;s decision to appoint Kennedy, known for his vaccine skepticism and conspiracy theories has sparked significant attention. The move aligns with Kennedy&#8217;s recent endorsement of Trump after ending his presidential bid.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Thank you <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> for your leadership and courage. I&#39;m committed to advancing your vision to Make America Healthy Again. We have a generational opportunity to bring together the greatest minds in science, medicine, industry, and government to put an end to the chronic…
&mdash; Robert F. Kennedy Jr (@RobertKennedyJr) <a href="https://twitter.com/RobertKennedyJr/status/1857198805919138235?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41947492/syros-pharmaceuticals-stock-sinks-as-pivotal-blood-cancer-trial-flunks-triggers-loan-default?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default</a>
Why It Matters: The appointment of Kennedy, a prominent critic of vaccines, as Health Secretary could signal a shift in national health policies. Trump&#8217;s choice has <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">elicited mixed reactions</a>, particularly among public health experts. Kennedy&#8217;s stance on vaccines may influence future health regulations and policies.
Kennedy&#8217;s views on vaccines <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">and health agencies diverge sharply</a> from mainstream medical consensus. He has consistently propagated debunked claims, including the false assertion that vaccines cause autism—a theory discredited by extensive scientific research. His nomination for HHS secretary comes amid declining vaccination rates, which have contributed to public health challenges such as 13 measles outbreaks reported in the U.S. this year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AbbVie&#8217;s Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio</a></li>
</ul>
Image via Shutterstock

Biotech

Health Care

Pre-Market Outlook

Markets

General

MRNA

NVAX

WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill

Morgan Stanley analyst Simeon Gutman maintains Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) with a Underweight and raises the price target from $8 to $12.

Morgan Stanley Maintains Underweight on Sally Beauty Holdings, Raises Price Target to $12

ValueAct Holdings, L.P. reported holdings worth $3.9 billion in the September quarter after it disclosed major changes in its 13F filing for the third quarter of current fiscal. 
What Happened: One of the major changes in its holdings during Q3 was the addition of 211,500 shares of Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) for $121.07 million, representing 3.08% of its total portfolio.
ValueAct Holdings is a hedge fund popularly known for its activist strategies, run by chief executive officer, Mason Morfit. An activist hedge fund usually follows an event-driven strategy and acquires sufficient equity to influence a company's policies, to increase company value. ValueAct has a long history of investing in technology companies and is generally considered to be more constructivist and collaborative than other activist funds.
ValueAct did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
In 2022, Brad Gerstner&#8216;s Altimeter Capital targeted Meta, urging the company to reduce its workforce. Gerstner articulated his concerns in <a href="https://www.benzinga.com/news/22/10/29380959/meta-investor-proposes-curb-on-employees-strength-metaverse-spending">a letter titled &#8220;Time to Get Fit.</a>
ValueAct fund's specific intentions remain unclear, but CEO Morfit is reportedly supportive of Meta CEO Mark Zuckerberg&#8217;s strategic focus on advancing artificial intelligence initiatives, <a href="https://www.cnbc.com/2024/11/12/activist-valueact-has-1-billion-stake-in-meta-sources-say.html">according</a> to CNBC.
Why It Matters: According to its Q3 <a href="https://13f.info/13f/000141881224000021/compare/000141881224000017">13F filing</a>, ValueAct has acquired a passive stake in the parent company of Facebook, Instagram and WhatsApp, namely, Meta. It is one of the largest companies to be targeted by an activist investor, with a market cap of nearly $1.5 trillion. The hedge fund also increased its investment in <a href="https://www.benzinga.com/m-a/24/01/36471982/disney-partners-with-valueact-capital-for-strategic-counsel-in-anticipation-of-2024-shareholder-meet">The Walt Disney Co</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) by adding 1.33 million shares taking its total value to $718.04 million in ValueAct&#8217;s portfolio.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42001972/chinese-retail-sales-pickup-in-october-heres-whats-happening-with-alibaba-jd-and-pinduoduo-shares">Chinese Retail Sales Pickup In October: Here&#8217;s What&#8217;s Happening With Alibaba, JD And Pinduoduo Shares</a>
Other Key Changes To The Portfolio
Apart from adding Meta, ValueAct has made some major changes to its portfolio which consists of ten holdings. The fund has increased its stake in the American video game developer Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) by adding 7.83 million shares in Q3. It now represents 8.81% of ValueAct&#8217;s portfolio, having a total value of $448.62 million.
Live Nation Entertainment Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>), Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and Liberty Media Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LLYVK#NASDAQ">LLYVK</a>) are other new holdings that ValueAct has added to its portfolio.
The hedge fund also reduced 806.96 thousand shares in Expedia Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) and completely exited Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), Finserv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>), New York Times Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>) and Flutter Entertainment PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>).
Read next: &nbsp;<a href="https://www.benzinga.com/general/market-summary/24/11/41968003/gold-drops-to-a-two-month-low-as-investors-turn-to-bitcoin-after-trumps-victory-but-this-economist-remains-confident-that-gold-will-surge" target="_blank" rel="noreferrer noopener">Gold Drops To A Two-Month Low As Investors Turn To Bitcoin After Trump's Victory, But This Economist Remains Confident That ‘Gold Will Surge'</a>
Image via Wikimedia Commons

Equities

Tech

EXPE

FLUT

LLYVK

RBLX

SPOT

Activist Hedge Fund ValueAct Boosts Meta Stake With $121M Bet, But CEO Morfit Supports Mark Zuckerberg's AI Vision: Here's What Investors Should Know

Morgan Stanley analyst Chris Quintero maintains BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Overweight and raises the price target from $70 to $80.

Morgan Stanley Maintains Overweight on BlackLine, Raises Price Target to $80

Morgan Stanley analyst Elizabeth Porter maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Equal-Weight and lowers the price target from $41 to $26.

ZETA

Morgan Stanley Maintains Equal-Weight on Zeta Global Holdings, Lowers Price Target to $26

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) with a Buy and maintains $11.5 price target.

IPHA

HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target

Morgan Stanley analyst Michael Phillips maintains Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) with a Underweight and raises the price target from $15 to $23.

LMND

Morgan Stanley Maintains Underweight on Lemonade, Raises Price Target to $23

TZUP

Thumzup shares are trading higher after the company announced its board of directors approved Bitcoin as a treasury reserve asset.

EYEN

Eyenovia shares are trading lower after the company announced that its CHAPERONE trial is not meeting its primary endpoint, prompting the discontinuation of the study and a review of the full data set to evaluate next steps for the program.

Morgan Stanley analyst Joseph Moore maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Equal-Weight and lowers the price target from $185 to $179.

Morgan Stanley Maintains Equal-Weight on Applied Mat, Lowers Price Target to $179

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Buy and maintains $46 price target.

ITOS

HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $46 Price Target

Smart Sand, Inc. (SND) Q2 2024 Earnings Call Transcript

Warning: SND is at high risk of performing badly

The latest update is out from Smart Sand ( ($SND) ). Smart Sand, Inc. has secured a new five-year senior secured asset-based credit facility of up ...

Smart Sand Secures New Credit Facility, Ends Previous Agreement

Smart Sand declares $0.10 dividend

Smart Sand ( ($SND) ) has issued an update. Smart Sand, Inc. has announced a special dividend of $0.10 per share and initiated an $10 million share...

Smart Sand Enhances Shareholder Returns with Dividend and Buyback

Smart Sand GAAP EPS of $0.00 misses by $0.01, revenue of $63.16M misses by $3.64M

Reports Q3 revenue $63.2M vs. $73.8M last year. Reports Q3 total tons sold of approximately 1.2M. "We are pleased to report that our continued focu...

Comments

Smart Sand

Smart Sand (SND) Opciones

Smart Sand (NASDAQ:SND) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL